Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH HBV VV-001 FTIH Phase I/II HBV Viral Vector + GSK3528869A in Chronic Hepatitis B
2023-510020-68-00Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 7
01
Overview
Phase 2, randomised, single-blind trial of GSK3528869A in hepatitis B (HBV), sponsored by GSK. Started Mar 2024; status: completed.
02
Drugs
GSK3528869A
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2023-510020-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510020-68-00.